235 related articles for article (PubMed ID: 11560493)
41. In vivo stabilization of mutant human transthyretin in transgenic mice.
Tagoe CE; Reixach N; Friske L; Mustra D; French D; Gallo G; Buxbaum JN
Amyloid; 2007 Sep; 14(3):227-36. PubMed ID: 17701470
[TBL] [Abstract][Full Text] [Related]
42. Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates.
Gupta S; Chhibber M; Sinha S; Surolia A
J Med Chem; 2007 Nov; 50(23):5589-99. PubMed ID: 17948976
[TBL] [Abstract][Full Text] [Related]
43. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.
Zhao L; Buxbaum JN; Reixach N
Biochemistry; 2013 Mar; 52(11):1913-26. PubMed ID: 23414091
[TBL] [Abstract][Full Text] [Related]
44. Evaluating the effect of mutations and ligand binding on transthyretin homotetramer dynamics.
Saldaño TE; Zanotti G; Parisi G; Fernandez-Alberti S
PLoS One; 2017; 12(7):e0181019. PubMed ID: 28704493
[TBL] [Abstract][Full Text] [Related]
45. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses?
Palaninathan SK
Curr Med Chem; 2012; 19(15):2324-42. PubMed ID: 22471981
[TBL] [Abstract][Full Text] [Related]
46. CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects.
Qiang L; Guan Y; Li X; Liu L; Mu Y; Sugano A; Takaoka Y; Sakaeda T; Imbimbo BP; Yamamura KI; Jin S; Li Z
Amyloid; 2017 Mar; 24(1):42-51. PubMed ID: 28393633
[TBL] [Abstract][Full Text] [Related]
47. Transthyretin stability is critical in assisting beta amyloid clearance- Relevance of transthyretin stabilization in Alzheimer's disease.
Alemi M; Silva SC; Santana I; Cardoso I
CNS Neurosci Ther; 2017 Jul; 23(7):605-619. PubMed ID: 28570028
[TBL] [Abstract][Full Text] [Related]
48. Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants.
Schwarzman AL; Tsiper M; Wente H; Wang A; Vitek MP; Vasiliev V; Goldgaber D
Amyloid; 2004 Mar; 11(1):1-9. PubMed ID: 15185492
[TBL] [Abstract][Full Text] [Related]
49. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses.
Connelly S; Choi S; Johnson SM; Kelly JW; Wilson IA
Curr Opin Struct Biol; 2010 Feb; 20(1):54-62. PubMed ID: 20133122
[TBL] [Abstract][Full Text] [Related]
50. Chemical dissection and reassembly of amyloid fibrils formed by a peptide fragment of transthyretin.
MacPhee CE; Dobson CM
J Mol Biol; 2000 Apr; 297(5):1203-15. PubMed ID: 10764584
[TBL] [Abstract][Full Text] [Related]
51. Inhibiting transthyretin amyloid fibril formation via protein stabilization.
Miroy GJ; Lai Z; Lashuel HA; Peterson SA; Strang C; Kelly JW
Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15051-6. PubMed ID: 8986762
[TBL] [Abstract][Full Text] [Related]
52. The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin.
Morais-de-Sá E; Neto-Silva RM; Pereira PJ; Saraiva MJ; Damas AM
Acta Crystallogr D Biol Crystallogr; 2006 May; 62(Pt 5):512-9. PubMed ID: 16627944
[TBL] [Abstract][Full Text] [Related]
53. Covalent reinforcement of a fragile region in the dimeric enzyme thymidylate synthase stabilizes the protein against chaotrope-induced unfolding.
Gokhale RS; Agarwalla S; Santi DV; Balaram P
Biochemistry; 1996 Jun; 35(22):7150-8. PubMed ID: 8679542
[TBL] [Abstract][Full Text] [Related]
54. Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two thyroxine binding sites.
Tomar D; Khan T; Singh RR; Mishra S; Gupta S; Surolia A; Salunke DM
PLoS One; 2012; 7(9):e43522. PubMed ID: 22973437
[TBL] [Abstract][Full Text] [Related]
55. Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses.
Almeida MR; Gales L; Damas AM; Cardoso I; Saraiva MJ
Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):587-96. PubMed ID: 16266291
[TBL] [Abstract][Full Text] [Related]
56. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro.
Colon W; Kelly JW
Biochemistry; 1992 Sep; 31(36):8654-60. PubMed ID: 1390650
[TBL] [Abstract][Full Text] [Related]
57. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.
Choi S; Reixach N; Connelly S; Johnson SM; Wilson IA; Kelly JW
J Am Chem Soc; 2010 Feb; 132(4):1359-70. PubMed ID: 20043671
[TBL] [Abstract][Full Text] [Related]
58. Structural evidence for asymmetric ligand binding to transthyretin.
Cianci M; Folli C; Zonta F; Florio P; Berni R; Zanotti G
Acta Crystallogr D Biol Crystallogr; 2015 Aug; 71(Pt 8):1582-92. PubMed ID: 26249340
[TBL] [Abstract][Full Text] [Related]
59. Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation.
Sant'Anna R; Almeida MR; Varejāo N; Gallego P; Esperante S; Ferreira P; Pereira-Henriques A; Palhano FL; de Carvalho M; Foguel D; Reverter D; Saraiva MJ; Ventura S
Sci Rep; 2017 Mar; 7():44709. PubMed ID: 28338000
[TBL] [Abstract][Full Text] [Related]
60. Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice?
Zhang Q; Kelly JW
Biochemistry; 2005 Jun; 44(25):9079-85. PubMed ID: 15966731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
